title: IL-17-targeting biologics aim to become standard of care in psoriasis.
authors.forename: Mark
authors.initials: M
authors.lastname: Ratner
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; C549079:ixekizumab